Clinical-stage radiotherapeutics company Radiopharm Theranostics has announced a new collaboration with GenesisCare under which they will seek to develop new treatments for some complex, hard-to-treat cancers.
GenesisCare is a leading provider of integrated cancer care and theranostics research.
The companies will conduct Phase 1 clinical trials in Australia to study the safety and tolerability of novel radiopharmaceuticals.
As part of the collaboration, GenesisCare’s Contract Research Organisation and Imaging Research Organisation, have been engaged to implement three Phase 1 clinical trials in Australia, involving Radiopharm’s platform of radiopharmaceutical nanobodies.
Radiopharmaceuticals are designed to deliver small doses of radiation to specifically targeted cells for either therapeutic or diagnostic purposes. Effective cancer radiopharmaceuticals require tumour-specific targets not found in healthy tissue. To date, the majority of clinical developments in radiopharmaceuticals have targeted metastatic prostate cancer and neuroendocrine tumours.
The three clinical trials will trial Radiopharm’s nanobody from its Nano-mAbs platform that targets the PDL1 expression in non-small cell lung cancer, its PTPu targeting peptide in Brain Tumors and PSA targeting antibody which targets free human prostate kallikrein (PSA) in prostate cancer cells.
Radiopharm’s CEO and managing director Riccardo Canevari said, “Radiopharmaceuticals are quickly becoming a highly promising therapeutic frontier in oncology, offering new hope to patients who may have exhausted all other treatment options.
“We are delighted to be extending and strengthening our partnership with GenesisCare, a world leader in cancer care, to advance the future of radiopharmaceuticals and improve access to innovative therapies for patients all over the world.”
GenesisCare’s chief scientific officer of research insights, Dr Danielle Meyrick, added, “We are delighted to be partnering with Radiopharm on its exciting pipeline of research in Australia. This R&D collaboration brings together two Australian-founded healthcare companies who share an interest in investigating and developing new therapies in Australia.”
